Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Bumetanide · 1 trial · 1 indication
Percent change in weight measured in kilograms from date of emergency department presentation (Day 0) to Day 7 of hospitalization, or date of discharge, whichever is earlier
| Arm | Type | Description |
|---|---|---|
| Bumetanide | EXPERIMENTAL | - |
| Furosemide | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Bumetanide | DRUG | Standard of care treatment with bumetanide (intravenous or oral administration) per treating clinician's orders |
| Furosemide | DRUG | Standard of care treatment with furosemide (intravenous or oral administration) per treating clinician's orders |
Inclusion Criteria: * History of liver cirrhosis * Clinician placed an order for bumetanide or furosemide in electronic health record within 24 hours of presentation to the hospital Exclusion Criteria: * Allergy to bumetanide or furosemide * Contraindication to diuretic administration (e.g. activ...
Bumetanide is a small molecule being studied for the treatment of cirrhosis. It is currently in Phase 3 clinical development for this indication. The drug is being evaluated in a randomized, controlled clinical trial in the United States.
Bumetanide is being developed by Johnson & Johnson, a company traded on the New York Stock Exchange under the ticker JNJ. The drug is currently in Phase 3 clinical development for cirrhosis.
Bumetanide is in Phase 3 clinical development for cirrhosis. It is an investigational drug and is not yet approved for this use. A Phase 3 trial is currently recruiting participants in the United States.
Bumetanide is being studied in a Phase 3 clinical trial with the identifier NCT06941415, titled "Bumetanide vs. Furosemide in Cirrhosis." The trial is recruiting 500 participants aged 18 years and older in the United States.
Bumetanide is not the same as furosemide. Bumetanide is being studied in a Phase 3 clinical trial that compares it directly against furosemide in patients with cirrhosis. The trial is designed to evaluate the effects of these two drugs in this patient population.